Impact of Multi-Professional Intervention on Health-Related Physical Fitness and Biomarkers in Overweight COVID-19 Survivors for 8 and 16 Weeks: A Non-Randomized Clinical Trial.

ingentiumby ingentium

In Clinical Trials Literature.

Publication date: Oct 14, 2024

Considering the diverse symptomatology of COVID-19-ranging from mild to severe cases-multi-professional interventions are crucial for enhancing physical recovery, nutritional status, and mental health outcomes in affected patients. Thus, this study aimed to investigate the effects of such an intervention on health-related physical fitness and biomarkers in overweight COVID-19 survivors with varying degrees of symptom severity after 8 weeks and 16 weeks. This non-randomized clinical trial included 59 overweight COVID-19 survivors (32 males and 27 females) divided into three groups: mild (n = 31), moderate (n = 13), and severe/critical (n = 15). The participants underwent a multi-professional program and were assessed for anthropometric and body composition (primary outcome), as well as physical fitness and biochemical markers (secondary outcome) 8 and 16 weeks before the intervention. After 8 weeks, time effects were observed for the maximum isometric handgrip strength (p < 0. 001), maximum isometric lumbar-traction strength (p = 0. 01), flexibility (p < 0. 001), abdominal strength-endurance (p < 0. 001), the sit-and-stand test (p < 0. 001), maximum oxygen consumption (p < 0. 001), and distance covered in the 6 min walk test (p < 0. 001). Additionally, time effects were also observed for fat mass (p = 0. 03), body fat percentage (p = 0. 02), abdominal circumference (p = 0. 01), total cholesterol (p < 0. 001), low-density lipoproteins (p < 0. 001), and glycated hemoglobin (p < 0. 001), with lower values after multi-professional interventions. After 16 weeks, the systolic and diastolic blood pressure showed significant reductions independently of the intervention group (p < 0. 001). These findings suggest that multi-professional interventions can provide substantial benefits for post-COVID-19 patients, regardless of the severity of their initial symptoms.

Open Access PDF

Concepts Keywords
Females coronavirus
Hemoglobin health promotion
Nutritional interdisciplinary study
Professional multi-professional team
Weeks rehabilitation research

Semantics

Type Source Name
disease IDO intervention
disease MESH Overweight
disease MESH COVID-19
disease MESH nutritional status
disease IDO symptom
drug DRUGBANK Oxygen
drug DRUGBANK Cholesterol
disease IDO blood
drug DRUGBANK Coenzyme M
disease MESH infection
disease MESH sequelae
disease MESH death
disease MESH viral infection
disease MESH cytokine storm
disease MESH syndrome
disease MESH dyspnea
disease MESH chest pain
disease MESH arthralgias
disease MESH obesity
disease MESH non communicable diseases
disease MESH diabetes mellitus
disease MESH hypertension
disease MESH dyslipidemia
disease MESH metabolic syndrome
disease MESH respiratory failure
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Human Serum Albumin
disease IDO history
disease MESH viral pneumonia
disease MESH hypoxia
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease MESH sepsis
disease MESH septic shock
disease MESH thrombosis
disease MESH contraindications
disease MESH myocarditis
disease MESH pericarditis
drug DRUGBANK Acetic acid
drug DRUGBANK Edetic Acid
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Creatinine
drug DRUGBANK Urea
drug DRUGBANK Magnesium
drug DRUGBANK Calcium
drug DRUGBANK Phosphorus
drug DRUGBANK Gold
disease MESH mental illness
pathway REACTOME Vitamins
disease MESH anxiety
disease MESH weight loss
drug DRUGBANK Water
disease MESH aids
disease MESH sweating
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO process
drug DRUGBANK Nonoxynol-9
disease MESH Post traumatic stress disorder
disease MESH lifestyle
disease MESH depressive symptoms
disease MESH Insomnia
disease MESH Binge eating
drug DRUGBANK Isoxaflutole
drug DRUGBANK Etoperidone
disease MESH chronic diseases
disease MESH cancer
disease MESH memory deficit
disease MESH Hypothyroidism
disease MESH Asthma
pathway KEGG Asthma
disease MESH Anxiety disorder
disease MESH inflammation
disease IDO host
disease MESH liver dysfunction
disease MESH abnormalities
drug DRUGBANK Chloride ion
disease MESH hypocalcemia
disease IDO production

Original Article

(Visited 2 times, 1 visits today)